Summary
Guerbet SA (Guerbet) is a manufacturer of contrast agents. The company provides a wide range of imaging products, solutions, and services for Computed Tomography (CT)/Cath Lab examinations, magnetic resonance imaging (MRI), and interventional imaging. CT/Cath Lab contrast agents consist of iodinated active ingredients and few examinations of the digestive tract use barium-based products. MRI imaging uses gadolinium complexes. Guerbet has a presence in Europe, Asia, and North and South America. The company offers products directly through its sales structure, distributors, and license holders. Guerbet is headquartered in Villepinte, France.This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guerbet SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Guerbet SA Company Overview
- Guerbet SA Company Snapshot
- Guerbet SA Pipeline Products and Ongoing Clinical Trials Overview
- Guerbet SA - Pipeline Analysis Overview
- Business Description
- Guerbet SA - Key Facts
- Guerbet SA - Major Products and Services
- Guerbet SA Pipeline Products by Development Stage
- Guerbet SA Pipeline Products Overview
- AI Based Diagnostic Tool - Liver Cancer
- AI Based Diagnostic Tool - Liver Cancer Product Overview
- AirFLO2
- AirFLO2 Product Overview
- Contrast Media Injector
- Contrast Media Injector Product Overview
- Contrast&Care 3.0
- Contrast&Care 3.0 Product Overview
- Microguidewire
- Microguidewire Product Overview
- Next Generation Optistar
- Next Generation Optistar Product Overview
- Next Generation Urologic Imagery System
- Next Generation Urologic Imagery System Product Overview
- Optivantage - Multi-Use Injector
- Optivantage - Multi-Use Injector Product Overview
- Optivantage - Multi-Use Injector V2
- Optivantage - Multi-Use Injector V2 Product Overview
- SeQure
- SeQure Product Overview
- Tumor Biomarker
- Tumor Biomarker Product Overview
- Ultra Hi-Flow Microcatheter
- Ultra Hi-Flow Microcatheter Product Overview
- Ultra-Low Profile Microcatheter
- Ultra-Low Profile Microcatheter Product Overview
- Watson Imaging Care Advisor System
- Watson Imaging Care Advisor System Product Overview
- Guerbet SA - Key Competitors
- Guerbet SA - Key Employees
- Guerbet SA - Key Employee Biographies
- Guerbet SA - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Guerbet SA, Recent Developments
- May 22, 2024: NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics
- Dec 11, 2023: Guerbet announces marketing authorisation approval of Elucirem (Gadopiclenol) in the European Union
- Nov 27, 2023: Guerbet to Spotlight Diagnostic Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting
- Nov 02, 2023: Guerbet to Spotlight Diagnostic and Interventional Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting
- Aug 08, 2023: Fresenius Kabi Further Expands Radiology Portfolio With Launch of Gadobutrol Injection
- Jul 17, 2023: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer
- Jun 16, 2023: Guerbet Receives 510(k) Clearance for DraKon
- May 23, 2023: Applied Radiology and Guerbet launch 'Elucirem (Gadopiclenol) injection | The Reveal Image Challenge'
- May 09, 2023: Guerbet announces ACR Committee on Drugs and contrast media classifies Elucirem (Gadopiclenol) injection a Group II agent
- Feb 13, 2023: Guerbet announces commercial launch and first patient dosing of Elucirem (Gadopiclenol) Injection, a novel new macrocyclic GBCA for use in contrast-enhanced Magnetic Resonance Imaging (MRI)
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Guerbet SA Pipeline Products and Ongoing Clinical Trials Overview
- Guerbet SA Pipeline Products by Equipment Type
- Guerbet SA Pipeline Products by Indication
- Guerbet SA, Key Facts
- Guerbet SA, Major Products and Services
- Guerbet SA Number of Pipeline Products by Development Stage
- Guerbet SA Pipeline Products Summary by Development Stage
- AI Based Diagnostic Tool - Liver Cancer - Product Status
- AI Based Diagnostic Tool - Liver Cancer - Product Description
- AirFLO2 - Product Status
- AirFLO2 - Product Description
- Contrast Media Injector - Product Status
- Contrast Media Injector - Product Description
- Contrast&Care 3.0 - Product Status
- Contrast&Care 3.0 - Product Description
- Microguidewire - Product Status
- Microguidewire - Product Description
- Next Generation Optistar - Product Status
- Next Generation Optistar - Product Description
- Next Generation Urologic Imagery System - Product Status
- Next Generation Urologic Imagery System - Product Description
- Optivantage - Multi-Use Injector - Product Status
- Optivantage - Multi-Use Injector - Product Description
- Optivantage - Multi-Use Injector V2 - Product Status
- Optivantage - Multi-Use Injector V2 - Product Description
- SeQure - Product Status
- SeQure - Product Description
- Tumor Biomarker - Product Status
- Tumor Biomarker - Product Description
- Ultra Hi-Flow Microcatheter - Product Status
- Ultra Hi-Flow Microcatheter - Product Description
- Ultra-Low Profile Microcatheter - Product Status
- Ultra-Low Profile Microcatheter - Product Description
- Watson Imaging Care Advisor System - Product Status
- Watson Imaging Care Advisor System - Product Description
- Guerbet SA, Key Employees
- Guerbet SA, Key Employee Biographies
- Guerbet SA, Other Locations
- Guerbet SA, Subsidiaries
- Glossary
- Guerbet SA Pipeline Products by Equipment Type
- Guerbet SA Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merit Medical Systems Inc
- GE HealthCare Technologies Inc
- ulrich GmbH & Co KG
- Boston Scientific Corp
- SuperSonic Imagine SA
- Nemoto Kyorindo Co Ltd
